(Il Sole 24 Ore Radiocor) - Milano, 7 mag - The Swiss pharmaceuticals company Roche said it has entered into a definitive merger agreement to acquire PathAI, a US-based company in digital pathology and the biopharma industry.

According to the terms of the agreement, Roche will make an upfront payment of 750 million dollars to purchase PathAI, with additional milestone payments up to a further 300 million.

Roche noted that the deal builds on a partnership with PathAI dating back to 2021 and scaled up in 2024 to include the development of AI-enabled companion diagnosic algorithms.

After transaction closing, which is expected in the second half of the year, PathAI will become part of Roche's diagnostics division.

'Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better tailored treatment regimens,' said Matt Sause, CEO of Roche Diagnostics. 'Bringing PathAI into Roche Diagnostics will allow us to combine their best-in-class digital pathology tools with our leading oncology diagnosis platforms to deliver better insights for physicians and potentially better.

outcomes for patients worldwide.'

(RADIOCOR) 07-05-26 12:21:49 (0402) 5 NNNN